Trials in progress
Poster Session 59

Sunday 18 March
15:45 - 17:15

Location: Blue Area, Room 2 (Level 0)
Chairs: A.S. Bjartell, Malmö (SE)  
G.I. Russo, Catania (IT)  
P. Sooriakumaran, London (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

798

Patient-reported outcomes in bladder cancer; a multicenter randomized controlled trial - a study design

By: Taarnhoej G.A., Johansen C., Dohn L.H., Lindberg H., Pappot H.
1Rigshospitalet, Dept. of Oncology, Copenhagen, Denmark, 2Danish Cancer Society, Unit of Survivorship, Copenhagen, Denmark, 3Herlev Hospital, Dept. of Oncology, Herlev, Denmark

799

Phase 2 study of pembrolizumab in patients with bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer:
KEYNOTE-057
To be confirmed

800

Evaluating safety and efficacy of INCB054828 as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma (UC): A phase 2 study of the European Association of Urology Research Foundation (EAU-RF)

By: Necchi A., Perez Gracia J.L., Loriot Y., Montorsi F., Bjartell A., Shariat S.
1Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Clinica Universidad de Navarra, Dept. of Medical Oncology, Pamplona, Spain, 3Gustave Roussy, Dept. of Medicine, Paris, France, 4European Association of Urology, Research Foundation, Arnhem, Netherlands, The, 5Vita Salute San Raffaele University, IRCCS San Raffaele Hospital, Urological Research Institute (URI), Milan, Italy, 6Skane University Hospital, Lund University, Dept. of Urology, Malmo, Sweden, 7Medical University of Vienna, Dept. of Urology, Vienna, Austria

801

KEYNOTE-361: Phase 3 trial of pembrolizumab ± chemotherapy versus chemotherapy alone in advanced urothelial cancer

1Barts Cancer Institute, Queen Mary University of London, Centre for Experimental
Peculiar: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC)

By: Necchi A., Mariani L., Anichini A., Messina A., Giannatempo P., Raggi D., Briganti A., Montorsi F.

1Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy,
2Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Clinical Epidemiology and Trials Organization Unit, Milan, Italy,
3Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Human Immunology, Milan, Italy,
4Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiology, Milan, Italy,
5Vita Salute San Raffaele University and Urological Research Institute (URI), IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy

Cabozantinib (CABO) plus durvalumab (DURVA) in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: The open-label, single-arm, phase 2 ARCADIA trial

By: Raggi D., Giannatempo P., Anichini A., Calareso G., Crippa F., Mariani L.

1Fondazione Ircs Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy,
2Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Human Tumor Immunology, Milan, Italy,
3Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiology, Milan, Italy,
4Fondazione IRCCS Istituto Nazionale dei Tumori, Nuclear Medicine - PET unit, Milan, Italy,
5Fondazione IRCCS Istituto Nazionale dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy

EV-103 Study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer
EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy

By: Rosenberg J. 1, Balar A. 2, O'Donnell P. 3, Heath E. 4, Hahn N. 5, Gartner E. 6, Melhem-Bertrandt A. 7, Petrylak D. 8

1Memorial Sloan Kettering Cancer Center, Dept. of Medicine, New York, United States of America, 2New York University, Cancer Institute, New York, United States of America, 3University of Colorado Hospital, Aurora, United States of America, 4Seattle Genetics, Inc., Dept. of Clinical Development, Bothell, United States of America, 5Astellas Pharma, Inc., Dept. of Development Medical Sciences, Northbrook, United States of America, 6Seattle Genetics, Inc, Dept. of Clinical Development, Bothell, United States of America, 7Memorial Sloan Kettering Cancer Center, Dept. of Medicine, New York, United States of America

Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP)

By: Morgans A. 1, Penson D. 2, Du L. 3, Jackson J. 4, Moses K. 2

1Northwestern University Feinberg School of Medicine, Dept. of Medicine, Chicago, United States of America, 2Vanderbilt University Medical Center, Dept. of Urologic Surgery, Nashville, United States of America, 3Vanderbilt University Medical Center, Dept. of Biostatistics, Nashville, United States of America, 4Vanderbilt University Medical Center, Dept. of Medicine, Nashville, United States of America

Early experience of a randomized controlled trial of radical prostatectomy for oligometastatic prostate cancer: Challenges to patient recruitment and effective solutions

By: Sooriakumaran P. 1, Rajan P. 1, Sridhar A. 1, Khetrapal P. 1, Nathan S. 1, Eden C. 2, Kelly J. 1, Hamdy F. 3, Wilson C. 4

1University College London Hospital, Dept. of Oncology, London, United Kingdom, 2Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom, 3Oxford University Hospital, Dept. of Urology, Oxford, United Kingdom, 4University of Bristol, Dept. of Population Health Sciences, Bristol, United Kingdom
IMbassador250: A phase III trial in patients with metastatic castration-resistant prostate cancer (mCRPC) comparing atezolizumab plus enzalutamide vs enzalutamide alone

By: Gillessen Sommer S., Powles T., Drake C., Rathkopf D., Narayanan S., Green M., Leng N., Schiff C., Sweeney C., Fizazi K.

1Kantonsspital St. Gallen, St. Gallen and University of Bern, Dept. of Oncology and Haematology, Bern, Switzerland, 2Barts Cancer Institute, Queen Mary University of London, Dept. of Experimental Cancer Medicine, London, United Kingdom, 3Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Dept. of Genitourinary Oncology, New York, United States of America, 4Memorial Sloan Kettering Cancer Center, Dept. of Genitourinary Oncology, New York, United States of America, 5Genentech, Inc., Dept. of Product Development Oncology, South San Francisco, United States of America, 6Genentech, Inc., Tecentriq GU Program, South San Francisco, United States of America, 7Genentech, Inc., PD Biometrics Biostatistics, South San Francisco, United States of America, 8Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, United States of America, 9Gustave Roussy, Dept. of Cancer Medicine, Villejuif, France

Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564


1Barts Cancer Institute, Dept of Experimental Cancer Medicine, London, United Kingdom, 2Duke Cancer Center, Dept. of Medical Oncology, Durham, United States of America, 3Macquarie University Hospital, Dept. of Medical Oncology and Clinical Research, Sydney, Australia, 4Texas Oncology Houston Memorial City, Dept. of Medical Oncology, Houston, United States of America, 5St Vincent Frontier Cancer Center, Dept. of Hematology and Oncology, Billings, United States of America, 6Adelaide Cancer Centre, Dept. of Medical Oncology, Kurralta Park, Australia, 7University of Ulsan College of Medicine, Dept. of Oncology and Internal Medicine, Seoul, Korea, South, 8Samsung Medical Center, Dept. of Medicine, Seoul, Korea, South, 9RBHI Ivanovo Regional Oncology Dispensary, Dept. of Medical Oncology, Ivanovo, Russia, 10Taipei Veterans General Hospital, Division of Urology, Taipei City, Taiwan, 11USC Norris Comprehensive Cancer Center, Division of Oncology, Los Angeles, United States of America, 12Merck & Co., Dept. of Medical Oncology, Kenilworth, United States of America, 13Dana-Farber Cancer Institute, Dept. of Oncology, Boston, United States of America

A phase III study of atezolizumab vs placebo as adjuvant therapy in patients with renal cell carcinoma at high risk of recurrence following resection (IMmotion010)

By: Bex A., Pal S., Rini B., Albiges L., Suárez C., Donaldson F., Qiu J., Hashimoto K., Uzzo R.

1Netherlands Cancer Institute, Dept. of Urology, Amsterdam, Netherlands, The, 2City of Hope Comprehensive Cancer Center, Dept. of Medical Oncology & Therapeutics Research, Duarte, United States of America, 3Cleveland Clinic, Dept. of Hematology &
| Challenges for the application of a novel cell-based therapeutic approach to treat SUI |
| Universitätsspital Zürich, Dept. of Urology, Zürich, Switzerland |